OHSU

IRB #

IRB00008706

Title

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-65 Years With Hematologic Malignancies

Principal Investigator

Richard Maziarz

Study Purpose

The purpose of this study is to find out how well subjects who receive a transplant with an investigational cord blood product respond to treatment.

Medical Condition(s)

Cancers of the blood and bone marrow in patients who are planning to undergo a double umbilical cord blood stem cell transplant.

Eligibility Criteria

--Your doctor has determined that allogeneic stem cell transplant is an appropriate treatment for your disease.
--Patients with cancers of the blood for whom a suitable related or unrelated adult stem cell donor is not available.
--Between the ages of 15 and 55
--Other criteria as dictated by the study protocol and the judgment of the study's Principal Investigator.

Age Range

15 - 65

Healthy Volunteers Needed

No

Duration of Participation

2 years

Minors Included

Yes

Contact

Nan Subbiah
Email: subbiahn@ohsu.edu

Sponsor

Fate Therapeutics, Inc.

Recruitment End

07/01/2014

Compensation Provided

No


Go Back